A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.

Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...

Marker Therapeutics’ MRKR shares have surged approximately 114% over the past three months, driven by strong momentum ...

For more information on these abstracts, visit the 2026 Tandem Meetings website.

Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Danish drugmaker Genmab said on Friday that its experimental drug for a type of blood cancer failed to meet the main goal in a late-stage study.

Genmab (GMAB) stock slips as trial data for the company's lymphoma therapy Epkinly (epcoritamab) marketed with AbbVie (ABBV) falls short of expectations. Read more here.

Jade Biosciences, Inc. ( JBIO) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 2:15 PM EST ...

It’s normal to feel overwhelmed when you’re diagnosed with large B-cell lymphoma (LBCL) and for that feeling to continue as you start treatment. Though a lot of things are out of your control — how ...

Meta-analysis shows greater response rate but research is hypothesis generating, experts s ...